TABLE 147: VIRAL LOAD < THRESHOLD GENOTYPE 1 TREATMENT-NAIVE: RELATIVE RISKS</th>

 AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

| TREATMENT | REFERENCE | RR (95% CRI) | RD % (95% CRL) |
|--------------------------------------|---------------|--|--|
| SOF24 + RBV24 | PR48 | 1.01 (0.71 to 1.19) | 0.67 (-23.35 to 14.48) |
| SOF12 + LDV12 | | 1.01 (0.49 to 1.23) | 0.63 (-40.39 to 17.20) |
| SOF24 + LDV24 | | 1.00 (0.30 to 1.27) | -0.17 (-56.22 to 20.73) |
| SOF8 + LDV8 | | 1.10 (0.44 to 1.29) | 8.05 (-44.02 to 21.90) |
| SOF8 + LDV8 + RBV8 | | 1.02 (0.36 to 1.27) | 1.74 (-50.35 to 20.38) |
| SOF12 + LDV12 | | | |
| + RBV12 | | 1.17 (0.67 to 1.33) | 13.80 (-26.51 to 24.45) |
| SOF24 + LDV24 | | 1.00 (0.24 to 1.27) | 0.25 (-60.45 to 20.27) |
| + RBV24 | | · · · · · · · · · · · · · · · · · · · | · · · · · · · · · · · · · · · · · · · |
| SIM12 PR24-48 RGT | | 1.16 (1.05 to 1.30) | 12.91 (3.94 to 21.66) |
| B44 PR48 | | 1.05 (0.27 to 1.33) | 3.74 (-62.16 to 23.95) |
| SOF24 + RBV (low dose) 24 | | 1.06 (0.41 to 1.27) | 4.59 (-47.00 to 20.73) |
| PAR/RIT12 + OMB12 | | 1.15 (0.50 to 1.33) | 12.22 (-39.51 to 24.14) |
| + DAS12 + RBV12 | | . , , | · · · · · |
| DCV24 + ASU24 | | 1.19 (1.08 to 1.34) | 15.44 (6.43 to 24.44) |
| SOF12 + PR12 | | 0.97 (0.14 to 1.28) | -2.59 (-69.60 to 21.34) |
| SOF12 + LDV12 SOF24 + LDV24 | SOF24 + RBV24 | 0.99 (0.53 to 1.39) | -0.52 (-36.59 to 23.88) -0.78 (-54.28 to 30.00) |
| SOF24 + LDV24 | | 0.99 (0.32 to 1.49) 1.07 (0.47 to 1.58) | 6.09 (-41.38 to 34.04) |
| SOF8 + LDV8 + RBV8 | | 1.07 (0.47 to 1.58) | 0.89 (-48.41 to 29.83) |
| SOF12 + LDV12 | | 1.01 (0.39 to 1.49) | 0.09 (-40.41 (0 29.03) |
| + RBV12 | | 1.14 (0.68 to 1.68) | 11.75 (-25.63 to 39.05) |
| SOF24 + LDV24 + RBV24 | | 1.00 (0.25 to 1.51) | -0.38 (-60.63 to 31.33) |
| SIM12 PR24-48 RGT | | 1.15 (0.97 to 1.69) | 12.02 (-2.45 to 38.36) |
| B44 PR48 | | 1.04 (0.26 to 1.66) | 3.52 (-64.24 to 37.79) |
| SOF24 + RBV (low dose) 24 | | 1.04 (0.44 to 1.42) | 3.36 (-41.44 to 26.28) |
| PAR/RIT12 + OMB12 | | 1.12 (0.52 to 1.66) | 10.19 (-38.22 to 37.85) |
| + DAS12 + RBV12 | | . , , | · · · · |
| DCV24 + ASU24 | | 1.18 (1.00 to 1.74) | 14.60 (-0.19 to 40.85) |
| SOF12 + PR12 | | 0.97 (0.14 to 1.48) | -2.77 (-69.09 to 29.98) |
| SOF24 + LDV24 | SOF12 + LDV12 | 0.99 (0.36 to 1.77) | -0.72 (-47.44 to 36.38) |
| SOF8 + LDV8 | | 1.07 (0.61 to 1.84) | 5.66 (-28.17 to 39.67) |
| SOF8 + LDV8 + RBV8 | | 1.02 (0.47 to 1.58) | 1.48 (-37.75 to 29.26) |
| SOF12 + LDV12 + RBV12 | | 1.14 (0.78 to 2.09) | 11.63 (-17.16 to 46.94) |
| SOF24 + LDV24 + RBV24 | | 1.00 (0.29 to 1.68) | 0.05 (-53.74 to 33.90) |
| SIM12 PR24-48 RGT | | 1.15 (0.95 to 2.38) | 12.29 (-4.59 to 53.88) |
| B44 PR48 | | 1.04 (0.27 to 2.26) | 3.11 (-64.53 to 50.29) |
| SOF24 + RBV (low dose) 24 | | 1.03 (0.44 to 2.06) | 2.80 (-44.40 to 44.11) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.11 (0.62 to 2.07) | 9.36 (-28.78 to 46.60) |

| TREATMENT | REFERENCE | RR (95% CRI) | RD % (95% CRL) |
|--------------------------------------|-----------------------|---------------------|--------------------------|
| DCV24 + ASU24 | | 1.18 (0.97 to 2.45) | 14.95 (-2.94 to 56.19) |
| SOF12 + PR12 | | 0.97 (0.15 to 1.79) | -2.64 (-67.06 to 37.57) |
| SOF8 + LDV8 | SOF24 + LDV24 | 1.08 (0.49 to 3.46) | 6.43 (-40.98 to 63.01) |
| SOF8 + LDV8 + RBV8 | | 1.02 (0.38 to 3.22) | 1.75 (–52.01 to 57.29) |
| SOF12 + LDV12 | | | |
| + RBV12 | | 1.14 (0.77 to 3.53) | 11.79 (-18.36 to 63.85) |
| SOF24 + LDV24 + RBV24 | | 1.00 (0.37 to 2.43) | -0.10 (-47.19 to 45.81) |
| SIM12 PR24-48 RGT | | 1.16 (0.92 to 3.95) | 13.15 (-7.71 to 69.87) |
| B44 PR48 | | 1.04 (0.27 to 3.38) | 2.98 (-64.32 to 62.82) |
| SOF24 + RBV (low dose) 24 | | 1.04 (0.40 to 3.41) | 3.21 (-52.72 to 60.34) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.12 (0.52 to 3.76) | 9.53 (-39.25 to 68.76) |
| DCV24 + ASU24 | | 1.19 (0.95 to 4.05) | 15.24 (-4.67 to 72.28) |
| SOF12 + PR12 | | 0.98 (0.26 to 1.68) | -1.97 (-46.66 to 29.66) |
| SOF8 + LDV8 + RBV8 | SOF8 + LDV8 | 0.96 (0.45 to 1.52) | -3.67 (-45.71 to 24.94) |
| SOF12 + LDV12 + RBV12 | | 1.05 (0.66 to 2.37) | 4.44 (-29.41 to 52.33) |
| SOF24 + LDV24 + RBV24 | | 0.93 (0.25 to 1.92) | -6.18 (-64.94 to 38.68) |
| SIM12 PR24-48 RGT | | 1.05 (0.91 to 2.65) | 4.62 (-8.72 to 57.69) |
| B44 PR48 | | 0.96 (0.26 to 2.38) | -3.34 (-67.78 to 50.87) |
| SOF24 + RBV (low dose) 24 | | 0.97 (0.39 to 2.23) | -2.75 (-53.07 to 45.21) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.03 (0.64 to 1.81) | 3.13 (-27.67 to 34.34) |
| DCV24 + ASU24 | | 1.08 (0.94 to 2.75) | 6.82 (-6.11 to 60.99) |
| SOF12 + PR12 | | 0.91 (0.13 to 1.99) | -7.74 (-77.53 to 40.50) |
| SOF12 + LDV12 + RBV12 | SOF8 + LDV8 + RBV8 | 1.12 (0.71 to 3.03) | 9.73 (-24.22 to 60.99) |
| SOF24 + LDV24 + RBV24 | | 0.98 (0.28 to 2.41) | -1.43 (-58.56 to 49.64) |
| SIM12 PR24-48 RGT | | 1.13 (0.92 to 3.21) | 11.01 (-7.35 to 64.13) |
| B44 PR48 | | 1.02 (0.28 to 2.82) | 1.30 (-64.78 to 57.18) |
| SOF24 + RBV (low dose) 24 | | 1.02 (0.43 to 2.69) | 1.68 (-49.00 to 53.24) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.10 (0.60 to 2.64) | 8.11 (-30.90 to 54.86) |
| DCV24 + ASU24 | | 1.16 (0.95 to 3.29) | 13.28 (-4.85 to 66.86) |
| SOF12 + PR12 | | 0.96 (0.14 to 2.50) | -3.17 (-74.63 to 50.92) |
| SOF24 + LDV24 + RBV24 | SOF12 + LDV12 + RBV12 | 0.88 (0.25 to 1.28) | -11.41 (-67.50 to 18.28) |
| SIM12 PR24-48 RGT | | 0.99 (0.88 to 1.75) | -1.16 (-11.53 to 40.07) |
| B44 PR48 | | 0.91 (0.24 to 1.59) | -8.20 (-73.97 to 33.64) |
| SOF24 + RBV (low dose) 24 | | 0.92 (0.35 to 1.54) | -8.11 (-60.69 to 30.58) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 0.99 (0.47 to 1.56) | -0.91 (-47.49 to 32.92) |

| TREATMENT | REFERENCE | RR (95% CRI) | RD % (95% CRL) |
|--------------------------------------|--------------------------------------|-------------------------------------|-----------------------------|
| DCV24 + ASU24 | | 1.01 (0.91 to 1.82) | 0.92 (-8.91 to 43.19) |
| SOF12 + PR12 | | 0.85 (0.13 to 1.30) | -14.26 (-79.60 to 19.42) |
| SIM12 PR24-48 RGT | SOF24 + LDV24 + RBV24 | 1.16 (0.93 to 4.85) | 12.93 (-7.17 to 73.42) |
| B44 PR48 | | 1.03 (0.28 to 4.13) | 2.71 (-66.06 to 66.29) |
| SOF24 + RBV (low dose) 24 | | 1.03 (0.42 to 3.93) | 2.76 (-50.20 to 65.21) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.12 (0.57 to 4.30) | 10.09 (-35.87 to 68.95) |
| DCV24 + ASU24 | | 1.19 (0.95 to 4.98) | 15.33 (-5.20 to 76.39) |
| SOF12 + PR12 | | 0.98 (0.18 to 2.82) | -1.55 (-65.35 to 50.83) |
| B44 PR48 | SIM12 PR24-48 RGT | 0.90 (0.24 to 1.11) | -9.13 (-73.22 to 9.49) |
| SOF24 + RBV (low dose) 24 | | 0.91 (0.35 to 1.09) | -8.23 (-60.60 to 7.61) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.00 (0.43 to 1.13) | -0.15 (-53.15 to 10.87) |
| DCV24 + ASU24 | | 1.03 (0.93 to 1.14) | 2.40 (-6.37 to 11.79) |
| SOF12 + PR12 | | 0.83 (0.12 to 1.09) | -15.51 (-82.38 to 8.33) |
| SOF24 + RBV (low dose) 24 | B44 PR48 | 1.01 (0.36 to 3.76) | 0.97 (-58.19 to 66.26) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.08 (0.48 to 4.04) | 6.74 (-45.95 to 71.58) |
| DCV24 + ASU24 | | 1.14 (0.93 to 4.29) | 11.54 (-6.77 to 74.04) |
| SOF12 + PR12 | | 0.95 (0.14 to 3.39) | -4.62 (-77.00 to 62.67) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | SOF24 + RBV (low dose) 24 | 1.07 (0.49 to 2.74) | 6.34 (-42.79 to 58.19) |
| DCV24 + ASU24 | | 1.12 (0.95 to 3.01) | 10.58 (-5.19 to 64.23) |
| SOF12 + PR12 | | 0.94 (0.14 to 2.39) | -5.11 (-75.73 to 51.39) |
| DCV24 + ASU24 | PAR/RIT12 + OMB12 + DAS12 + RBV12 | 1.03 (0.91 to 2.41) | 2.55 (-8.47 to 56.21) |
| SOF12 + PR12 | | 0.87 (0.13 to 1.90) | -11.82 (-81.86 to 38.89) |
| SOF12 + PR12 | DCV24 + ASU24 | 0.82 (0.11 to 1.06) | -17.79 (-85.02 to 5.22) |
| Random effect model | Residual deviance | 24.72 vs. 29 data points | |
| | Deviance information criteria | 117.779 | |
| Fixed effect model | Residual deviance | 23.87 vs. 29 data points | |
| | Deviance information criteria | 23.87 VS. 29 data points 114.047 | |
| | | 1 | 17.071 |

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin;

RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir;

SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus. Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.